SRXH

Business Context and Reporting Period

Company: SRx Health Solutions, Inc. (SRXH)
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 31, 2025 (Q1 Fiscal 2026)
Business Status: The Company underwent a significant restructuring. Following a reverse merger in April 2025, the former Canadian specialty pharmacy and healthcare operations (SRx Canada) were classified as discontinued operations after filing for protection under the Companies' Creditors Arrangement Act (CCAA) in August 2025. Continuing operations now consist solely of the Consumer Products segment, focused on premium pet health and nutrition (Halo brand).

Key Financial Metrics

Note: Prior period results for continuing operations are not presented as the Halo business only became the reporting entity following the April 2025 merger. Prior year net loss relates entirely to discontinued operations.

Material Changes and Drivers

• Revenue Generation: Net sales of $2.8 million were generated exclusively from the Halo pet food business. 92% of sales came from the Digital channel, with two wholesale customers representing over 10% of total sales each.
• Loss on Extinguishment of Debt: A significant non-cash charge of $3.1 million was recognized due to the settlement and extinguishment of the July 2025 senior secured convertible notes in October 2025.
• Digital Asset Volatility: The Company purchased $8.5 million in digital assets (Bitcoin, Ethereum, etc.) during the quarter. A $0.5 million unrealized loss was recorded due to fair value adjustments.
• Liquidity Improvement: Cash balances increased from $1.3 million to $13.1 million, driven by $23.1 million in financing proceeds (issuance of common and preferred stock) offset by operating losses and digital asset purchases.
• Discontinued Operations: The former SRx Canada healthcare segment contributed a net loss of $4.0 million in the prior year but has zero activity in the current quarter as operations were wound down.

Outlook, Risks, and Management Commentary

• Strategic Focus: Management is focused on stabilizing the Consumer Products segment, optimizing cost structure, and re-establishing a growth path for the Halo brand. The capital-intensive healthcare model has been replaced by a streamlined pet product business.
• Financing Activities: The Company secured significant liquidity through an ELOC (Equity Line of Credit) amended to $1.0 billion and an October PIPE financing involving Series A preferred stock and warrants. A $20 million ELOC Commitment Note was issued as consideration for the ELOC amendment.
• Listing Compliance: The Company received notice from NYSE American accepting its plan to regain compliance with listing standards, granting an extension period through July 14, 2026.
• Key Risks:
  • Liquidity: Dependence on the ELOC and ability to raise capital to service debt and fund operations.
  • Digital Assets: Significant exposure to price volatility and regulatory uncertainty regarding crypto assets.
  • Customer Concentration: High reliance on two major digital wholesale customers (88% of gross sales).
  • Debt Obligations: Significant short-term convertible debt ($21 million) maturing in July 2026.

Investor Verification Checklist

• Debt Maturity: Verify the repayment plan for the $21.0 million ELOC Commitment Note maturing in July 2026.
• Digital Asset Valuation: Confirm the fair value methodology and custody arrangements for the $8.0 million digital asset portfolio.
• Customer Concentration: Assess the risk associated with two customers representing 88% of gross sales.
• Preferred Stock Redemption: Review the terms of the Series A preferred stock redemption (aggregate price of $21.8 million) scheduled for February 2026.
• Going Concern: Evaluate the sufficiency of the $13.1 million cash balance against operating burn rates and upcoming debt obligations.